↓ Skip to main content

Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.

Overview of attention for article published in European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] NLMUID: 9717360, October 2021
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
11 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.
Published in
European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] NLMUID: 9717360, October 2021
DOI 10.26355/eurrev_202110_26993
Pubmed ID
Authors

H J Lee, G H Jeong, H Li, M S Kim, J S Kim, S J Park, Y J Han, K H Lee, A Kronbichler, S H Hong, R A Ghayda, C Luchini, A Nottegar, A Koyanagi, L Smith, L Jacob, E Dragioti, J Radua, S Cargnin, S Terrazzino, T Thompson, D K Yon, S W Lee, J M Yang, P Wasuwanich, J I Shin, G Gamerith

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 18%
Student > Postgraduate 2 18%
Student > Bachelor 2 18%
Lecturer 1 9%
Researcher 1 9%
Other 1 9%
Unknown 2 18%
Readers by discipline Count As %
Medicine and Dentistry 4 36%
Unspecified 2 18%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%
Business, Management and Accounting 1 9%
Biochemistry, Genetics and Molecular Biology 1 9%
Other 0 0%
Unknown 2 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2021.
All research outputs
#23,069,091
of 25,711,518 outputs
Outputs from European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] NLMUID: 9717360
#1,901
of 3,216 outputs
Outputs of similar age
#376,693
of 438,466 outputs
Outputs of similar age from European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] NLMUID: 9717360
#45
of 69 outputs
Altmetric has tracked 25,711,518 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,216 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,466 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.